Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== 10 January === The SAF retook the town of Um al-Qura in Gezira State, 40 kilometers east of Wad Madani, from the RSF, while the SAF-allied Sudan Shield Forces retook Wad al-Abyad, 20 kilometres from the Hantoub bridge. At least 26 people were killed in an attack by the Sudan Shield Forces on the village of Tayba in Gezira State.
Most of the run-through schemes are in stand-alone specialties (e.g., radiology, public health, histopathology), but there are also a few traditionally surgical specialities which can be entered directly without completing core surgical training (e.g., neurosurgery, obstetrics & gynaecology, ophthalmology). The length of this training varies; for example, general practice is three years while radiology is five years. The UK grade equivalent of a US fellow in medical/surgical sub-specialties is the specialty registrar (ST3–ST9) grade of sub-specialty training. However, while US fellowship programmes are generally 2–3 years in duration after completing the residency, UK trainees spend 4–7 years. This generally includes service provision in the main specialty; this discrepancy lies in the competing demands of NHS service provision, and UK postgraduate training stipulating that even specialist registrars must be able to accommodate the general acute medical take—almost equivalent to what dedicated attending internists perform in the United States (they still remain minimally supervised for these duties). In 2024, the British Medical Association (BMA) advocated for all junior doctors to be renamed residents to prevent the confusion between resident doctors and medical students that terms such as "junior doctors" and "doctors in training" produce.
==== Chronic non-cancer pain ==== Guidelines have suggested that the risks of opioids are likely greater than their benefits when used for most non-cancer chronic conditions including headaches, back pain, and fibromyalgia. Thus they should be used cautiously in chronic non-cancer pain. If used, the benefits and harm should be reassessed at least every three months. For treating chronic pain, opioids are an option after other less risky pain relievers have been considered, including paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen. Some types of chronic pain, including the pain caused by fibromyalgia or migraine, are preferentially treated with non-opioid drugs. The efficacy of using opioids to lessen chronic neuropathic pain is uncertain. Opioids are contraindicated as a first-line treatment for headache because they impair alertness, bring risk of dependence, and increase the risk that episodic headaches will become chronic. Opioids can also cause heightened sensitivity to headache pain. When other treatments fail or are unavailable, opioids may be appropriate for treating headache if the patient can be monitored to prevent the development of chronic headache. Starting in the late 20th century, there was an increase in the use of opioids in the management of non-malignant chronic pain. This practice has led to a growing problem with addiction and misuse of opioids, the opioid epidemic.
=== Sexual dysfunction === Selegiline has been assessed for treatment of sexual dysfunction induced by antipsychotics in people with schizophrenia, but was not effective in a single small clinical study. It also did not improve sexual function in men with depression, but did improve several domains of sexual function in women with depression.
Sources: en.wikipedia.org
== Preparation == Bark is collected during Qingming (Pure Brightness), the fifth solar term (April 4–20). It is sun-dried and cut into slices. The bark may be used raw or fried with salt. Typical dosage is 3–10 grams. A variety of methods of water and ethanol extraction may have differing activities (see below) and methods such as "semi-bionic extraction" have been investigated to improve yields. Some pharmacological activities of the bark can be standardized by analyzing the level of berberine using a monoclonal antibody, thin-layer chromatography, HPLC, potentiometry, or acidic potassium permanganate chemiluminescence. There are quantitative differences between the two species of Cortex Phellodendri (P. amurense and chinense) and it has been suggested that they should be used as separate resources in the clinic. An analysis of 31 commercial samples in 1993 found that the total level of five alkaloids in samples of P. wilsonii and P. amurense var. sachalinense was 4.1% (mostly berberine), while the level in P. amurense and Ph. chinense was 1.5%. The levels of four harmful trace heavy metals (arsenic, cadmium, mercury, and thallium) in P. chinense for export are limited by the Pharmacopoeia of the People's Republic of China and the Green Trade Standard for Importing and Exporting Medicinal Plant and Preparation.
The heteronuclear single quantum coherence or heteronuclear single quantum correlation experiment, normally abbreviated as HSQC, is used frequently in NMR spectroscopy of organic molecules and is of particular significance in the field of protein NMR. The experiment was first described by Geoffrey Bodenhausen and D. J. Ruben in 1980. The resulting spectrum is two-dimensional (2D) with one axis for proton (1H) and the other for a heteronucleus (an atomic nucleus other than a proton), which is usually 13C or 15N. The spectrum contains a peak for each unique proton attached to the heteronucleus being considered. The 2D HSQC can also be combined with other experiments in higher-dimensional NMR experiments, such as NOESY-HSQC or TOCSY-HSQC.
In pharmacology, inorganic bromide compounds, especially potassium bromide, were frequently used as general sedatives in the 19th and early 20th century. Porsche in 1828 used KBr for scrofula. Otto Graf in a 1842 thesis reported that he became impotent while taking 1.8 g/day for two weeks as a self-experiment, and recovered sexual function upon ending the intake. Huette in 1850 reported that it caused impotence and loss of libido. Charles Locock in 1856 administered to women with "hysterical epilepsy", whose symptoms included masturbation. Locock theorized that masturbation caused epilepsy in these cases, and adiminstered KBr based on its anaphrodisiac effect. It caused a remission of epilepsy and masturbation. Locock did not understand KBr as an anticonvulsant in its own right. Subsequent research in the 1860s established KBr as generally effective for epilepsy, not just "hysterical" epilepsy, and it came into widespread use. In 1901, the Hospital for the Palsied and Epileptic in London was buying ~2 ton/year of KBr. Bromides also were recommended for insomnia, palpitations, and general neuroses, until barbituates supplanted them around 1930. It remained the only effective anticonvulsant, until the discovery of phenobarbital in 1912. Bromides in the form of simple salts are still used as anticonvulsants in both veterinary and human medicine, although the latter use varies from country to country. For example, the U.S.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.